Patents by Inventor Keiichi Okimura
Keiichi Okimura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240110186Abstract: A method produces a hairpin single-stranded RNA molecule capable of inhibiting expression of a target gene, including the step of reacting a first single-stranded oligo-RNA molecule represented by formula (I) with a second single-stranded oligo-RNA molecule represented by formula (II) in a mixed solvent including a buffer solution and a hydrophilic organic solvent in the presence of a dehydration condensation agent: 5?-Xc-Lx1 . . . (I) and Lx2-X—Y-Ly-Yc-3? . . . (II), wherein the dehydration condensation agent is selected from the group consisting of a triazine-based dehydration condensation agent, a uronium-based dehydration condensation agent including an N-hydroxy nitrogen-containing aromatic ring structure, a carbodiimide-based dehydration condensation agent, a 2-halopyridinium-based dehydration condensation agent, and a formamidinium-based dehydration condensation agent.Type: ApplicationFiled: September 1, 2023Publication date: April 4, 2024Inventors: Kyohei Koshimoto, Katsuhiko Iseki, Hideaki Inada, Tatsuya Fujita, Keiichi Okimura, Munetaka Kunishima, Tadaaki Ohgi, Eriko Aoki
-
Patent number: 11920131Abstract: A method produces a hairpin single-stranded RNA molecule capable of inhibiting expression of a target gene, the method including: (i) an annealing step of annealing a first single-stranded oligoRNA molecule and a second single-stranded oligoRNA molecule; and (ii) a ligation step of ligating 3? end of the first single-stranded oligoRNA molecule and 5? end of the second single-stranded oligoRNA molecule by an Rnl2 family ligase, wherein a sequence produced by ligating the first single-stranded oligoRNA molecule and the second single-stranded oligoRNA molecule includes a gene expression-inhibiting sequence for the target gene.Type: GrantFiled: March 29, 2019Date of Patent: March 5, 2024Assignee: Toray Industries, Inc.Inventors: Hideaki Inada, Katsuhiko Iseki, Keiichi Okimura, Masato Sanosaka, Ayumi Takashina
-
Patent number: 11891602Abstract: A method produces a hairpin single-stranded RNA molecule capable of inhibiting expression of a target gene, including the step of reacting a first single-stranded oligo-RNA molecule represented by formula (I) with a second single-stranded oligo-RNA molecule represented by formula (II) in a mixed solvent including a buffer solution and a hydrophilic organic solvent in the presence of a dehydration condensation agent: 5?-Xc-Lx1 (I) and Lx2-X—Y-Ly-Yc-3? (II), wherein the dehydration condensation agent is selected from the group consisting of a triazine-based dehydration condensation agent, a uronium-based dehydration condensation agent including an N-hydroxy nitrogen-containing aromatic ring structure, a carbodiimide-based dehydration condensation agent, a 2-halopyridinium-based dehydration condensation agent, and a formamidinium-based dehydration condensation agent.Type: GrantFiled: October 2, 2019Date of Patent: February 6, 2024Assignee: Toray Industries, Inc.Inventors: Kyohei Koshimoto, Katsuhiko Iseki, Hideaki Inada, Tatsuya Fujita, Keiichi Okimura, Munetaka Kunishima, Tadaaki Ohgi, Eriko Aoki
-
Publication number: 20210317495Abstract: A method produces a hairpin single-stranded RNA molecule capable of inhibiting expression of a target gene, including the step of reacting a first single-stranded oligo-RNA molecule represented by formula (I) with a second single-stranded oligo-RNA molecule represented by formula (II) in a mixed solvent including a buffer solution and a hydrophilic organic solvent in the presence of a dehydration condensation agent: 5?-Xc-Lx1 (I) and Lx2-X—Y-Ly-Yc-3? (II), wherein the dehydration condensation agent is selected from the group consisting of a triazine-based dehydration condensation agent, a uronium-based dehydration condensation agent including an N-hydroxy nitrogen-containing aromatic ring structure, a carbodiimide-based dehydration condensation agent, a 2-halopyridinium-based dehydration condensation agent, and a formamidinium-based dehydration condensation agent.Type: ApplicationFiled: October 2, 2019Publication date: October 14, 2021Inventors: Kyohei Koshimoto, Katsuhiko Iseki, Hideaki Inada, Tatsuya Fujita, Keiichi Okimura, Munetaka Kunishima, Tadaaki Ohgi, Eriko Aoki
-
Publication number: 20210024930Abstract: A method produces a hairpin single-stranded RNA molecule capable of inhibiting expression of a target gene, the method including: (i) an annealing step of annealing a first single-stranded oligoRNA molecule and a second single-stranded oligoRNA molecule; and (ii) a ligation step of ligating 3? end of the first single-stranded oligoRNA molecule and 5? end of the second single-stranded oligoRNA molecule by an Rnl2 family ligase, wherein a sequence produced by ligating the first single-stranded oligoRNA molecule and the second single-stranded oligoRNA molecule includes a gene expression-inhibiting sequence for the target gene.Type: ApplicationFiled: March 29, 2019Publication date: January 28, 2021Inventors: Hideaki Inada, Katsuhiko Iseki, Keiichi Okimura, Masato Sanosaka, Ayumi Takashina
-
Patent number: 10662156Abstract: A compound has a guanidine skeleton that inhibits the protease activity of MALT1 and exerts a therapeutic or prophylactic effect on autoimmune disease such as psoriasis or allergic disease such as atopic dermatitis. The guanidine derivative is typified by the following formula or a pharmacologically acceptable salt thereof.Type: GrantFiled: July 28, 2017Date of Patent: May 26, 2020Assignee: Toray Industries, Inc.Inventors: Yoshitaka Numajiri, Keiichi Okimura, Yuki Matsumura, Kennunettsu Asaba, Tomohide Masuda, Kazuyuki Tokumaru, Yasufumi Goto, Shigeo Fujii
-
Patent number: 10519106Abstract: A compound has inhibitory activity on Discoidin Domain Receptor 1. The compound includes a urea derivative represented by the formula below or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 31, 2016Date of Patent: December 31, 2019Assignee: Toray Industries, Inc.Inventors: Yukihiro Nishio, Masashi Yamamoto, Yuko Kubota, Hideyuki Tsutsui, Tomohide Masuda, Keiichi Okimura, Syuji Udagawa, Mie Kaino, Hiroyuki Meguro, Yumiko Sekiya
-
Publication number: 20190233376Abstract: A compound has a guanidine skeleton that inhibits the protease activity of MALT1 and exerts a therapeutic or prophylactic effect on autoimmune disease such as psoriasis or allergic disease such as atopic dermatitis. The guanidine derivative is typified by the following formula or a pharmacologically acceptable salt thereof.Type: ApplicationFiled: July 28, 2017Publication date: August 1, 2019Inventors: Yoshitaka Numajiri, Keiichi Okimura, Yuki Matsumura, Kennunettsu Asaba, Tomohide Masuda, Kazuyuki Tokumaru, Yasufumi Goto, Shigeo Fujii
-
Patent number: 10280145Abstract: A compound has inhibitory activity on Discoidin Domain Receptor 1. A urea derivative is represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein, R1 is trifluoromethyl, trifluoromethoxy, or pentafluorosulfanyl; each R2 is independently a hydrogen atom or methyl which is optionally substituted by one hydroxyl or one saturated heterocyclyl having four to six ring-forming atoms; R3 is a hydrogen atom, halogen atom, C1-C3 alkyl, saturated heterocyclyl having four to six ring-forming atoms and optionally having an oxo group, or R5O—; and R4 is phenyl, pyridyl, pyridazinyl, or pyrimidinyl, which phenyl, pyridyl, pyridazinyl, or pyrimidinyl is optionally substituted by one R6.Type: GrantFiled: August 31, 2016Date of Patent: May 7, 2019Assignee: Toray Industries, Inc.Inventors: Yukihiro Nishio, Yuko Kubota, Masashi Yamamoto, Yutaka Nishimura, Tomohide Masuda, Hideyuki Tsutsui, Keiichi Okimura, Syuji Udagawa, Mie Kaino, Hiroyuki Meguro, Yumiko Sekiya
-
Publication number: 20190010117Abstract: A compound has inhibitory activity on Discoidin Domain Receptor 1. The compound includes a urea derivative represented by the formula below or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: August 31, 2016Publication date: January 10, 2019Inventors: Yukihiro Nishio, Masashi Yamamoto, Yuko Kubota, Hideyuki Tsutsui, Tomohide Masuda, Keiichi Okimura, Syuji Udagawa, Mie Kaino, Hiroyuki Meguro, Yumiko Sekiya
-
Publication number: 20180237398Abstract: A compound has inhibitory activity on Discoidin Domain Receptor 1. A urea derivative is represented by the formula (I) or a pharmaceutically acceptable salt thereof: wherein, R1 is trifluoromethyl, trifluoromethoxy, or pentafluorosulfanyl; each R2 is independently a hydrogen atom or methyl which is optionally substituted by one hydroxyl or one saturated heterocyclyl having four to six ring-forming atoms; R3 is a hydrogen atom, halogen atom, C1-C3 alkyl, saturated heterocyclyl having four to six ring-forming atoms and optionally having an oxo group, or R5O—; and R4 is phenyl, pyridyl, pyridazinyl, or pyrimidinyl, which phenyl, pyridyl, pyridazinyl, or pyrimidinyl is optionally substituted by one R6.Type: ApplicationFiled: August 31, 2016Publication date: August 23, 2018Inventors: Yukihiro Nishio, Yuko Kubota, Masashi Yamamoto, Yutaka Nishimura, Tomohide Masuda, Hideyuki Tsutsui, Keiichi Okimura, Syuji Udagawa, Mie Kaino, Hiroyuki Meguro, Yumiko Sekiya